Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.
Sarah Walters, Camille Maringe, Michel P Coleman...
https://pubmed.ncbi.nlm.nih.gov/23399908/Actively Recruiting
Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2026-04-09
28
Participants Needed
1
Research Sites
53 weeks
Total Duration
This research aims to evaluate the effect of adding glutamine plus Lactobacillus reuteri to an astringent diet in patients with advanced non-small cell lung cancer NSCLC who have EGFR mutations and are receiving tyrosine kinase inhibitor TKI therapy. The main question is whether this supplemented diet can help prevent diarrhea caused by TKI treatment. This is an open-label randomized clinical trial sponsored by the Instituto Nacional de Cancerologia de Mexico. Participants in the experimental group will receive an astringent diet supplemented with two sachets daily, each containing 10 grams of glutamine and 100 million colony forming units of Lactobacillus reuteri, for up to six weeks or until death. The control group will follow a standard astringent diet without supplementation. All patients will receive nutritional counseling every two weeks during the study. Throughout the trial, researchers will monitor diarrhea toxicity and assess quality of life using chronic illness therapy tools and lung cancer-specific questionnaires every two weeks from the first dose of TKI therapy up to six weeks. Gastrointestinal toxicity grades and health-related quality of life measures will also be recorded. The study period includes regular evaluations to understand the effects of the diet supplement on TKI-related diarrhea and patient well-being.
CONDITIONS
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
O
Oscar G Arrieta Rodriguez, M.D., M.Sc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Instituto Nacional de Cancerologia de Mexico
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks or until death
Participants receive either an astringent diet supplemented with Glutamine plus Lactobacillus reuteri twice daily or a standard astringent diet while receiving EGFR tyrosine kinase inhibitor therapy. Nutritional counseling is provided every two weeks.
Visits every two weeks for nutritional counseling and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sarah Walters, Camille Maringe, Michel P Coleman...
https://pubmed.ncbi.nlm.nih.gov/23399908/Najate Achamrah, Pierre Déchelotte, Moïse Coëffier
https://pubmed.ncbi.nlm.nih.gov/27749689/Kate R Secombe, Ysabella Z A Van Sebille, Bronwen J Mayo...
https://pubmed.ncbi.nlm.nih.gov/32493068/Karla Sánchez-Lara, Jenny G Turcott, Eva Juárez...
https://pubmed.ncbi.nlm.nih.gov/22489794/Oscar Arrieta, Rosa M Michel Ortega, Geraldine Villanueva-Rodríguez...
https://pubmed.ncbi.nlm.nih.gov/20170547/Peter Goldstraw, David Ball, James R Jett...
https://pubmed.ncbi.nlm.nih.gov/21565398/Óscar Arrieta, Carolina Núñez-Valencia, Leonardo Reynoso-Erazo...
https://pubmed.ncbi.nlm.nih.gov/22387006/Instituto Nacional de Cancerologia de Mexico
Lead Sponsor